260 related articles for article (PubMed ID: 24836354)
1. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.
McGee P; Steffes M; Nowicki M; Bayless M; Gubitosi-Klug R; Cleary P; Lachin J; Palmer J;
Diabet Med; 2014 Oct; 31(10):1264-8. PubMed ID: 24836354
[TBL] [Abstract][Full Text] [Related]
2. Characterization of residual β cell function in long-standing type 1 diabetes.
Sherr JL; Ghazi T; Wurtz A; Rink L; Herold KC
Diabetes Metab Res Rev; 2014 Feb; 30(2):154-62. PubMed ID: 24115337
[TBL] [Abstract][Full Text] [Related]
3. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions.
Gubitosi-Klug RA;
Diabetes Care; 2014; 37(1):44-9. PubMed ID: 24356597
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
[TBL] [Abstract][Full Text] [Related]
5. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.
; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R
JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339
[TBL] [Abstract][Full Text] [Related]
6. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.
Gubitosi-Klug RA; Braffett BH; Hitt S; Arends V; Uschner D; Jones K; Diminick L; Karger AB; Paterson AD; Roshandel D; Marcovina S; Lachin JM; Steffes M; Palmer JP;
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529168
[TBL] [Abstract][Full Text] [Related]
7. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.
Nathan DM;
Diabetes Care; 2014; 37(1):9-16. PubMed ID: 24356592
[TBL] [Abstract][Full Text] [Related]
8. Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.
Hao W; Gitelman S; DiMeglio LA; Boulware D; Greenbaum CJ;
Diabetes Care; 2016 Oct; 39(10):1664-70. PubMed ID: 27422577
[TBL] [Abstract][Full Text] [Related]
9. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Steffes MW; Sibley S; Jackson M; Thomas W
Diabetes Care; 2003 Mar; 26(3):832-6. PubMed ID: 12610045
[TBL] [Abstract][Full Text] [Related]
10. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study.
Cengiz E; Cheng P; Ruedy KJ; Kollman C; Tamborlane WV; Klingensmith GJ; Gal RL; Silverstein J; Lee J; Redondo MJ; Beck RW;
Pediatr Diabetes; 2017 Nov; 18(7):566-573. PubMed ID: 27758023
[TBL] [Abstract][Full Text] [Related]
12. A case of idiopathic type 1 diabetes with subsequent recovery of endogenous insulin secretion despite initial diagnosis of fulminant type 1 diabetes.
Kaneko K; Satake C; Yamamoto J; Takahashi H; Sawada S; Imai J; Yamada T; Katagiri H
Endocr J; 2017 Mar; 64(3):369-374. PubMed ID: 28070056
[TBL] [Abstract][Full Text] [Related]
13. Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes.
Max Andersen ML; Hougaard P; Pörksen S; Nielsen LB; Fredheim S; Svensson J; Thomsen J; Vikre-Jørgensen J; Hertel T; Petersen JS; Hansen L; Mortensen HB
Pediatr Diabetes; 2014 Nov; 15(7):469-76. PubMed ID: 25287319
[TBL] [Abstract][Full Text] [Related]
14. The impact of insulin administration during the mixed meal tolerance test.
Besser RE; Jones AG; McDonald TJ; Shields BM; Knight BA; Hattersley AT
Diabet Med; 2012 Oct; 29(10):1279-84. PubMed ID: 22435709
[TBL] [Abstract][Full Text] [Related]
15. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
16. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
[TBL] [Abstract][Full Text] [Related]
17. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
Wang Y; Gong C; Cao B; Meng X; Wei L; Wu D; Liang X; Li W; Liu M; Gu Y; Su C
Pediatr Diabetes; 2017 May; 18(3):196-203. PubMed ID: 26947770
[TBL] [Abstract][Full Text] [Related]
18. Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration.
Ruan Y; Willemsen RH; Wilinska ME; Tauschmann M; Dunger DB; Hovorka R
Pediatr Diabetes; 2019 May; 20(3):282-285. PubMed ID: 30652426
[TBL] [Abstract][Full Text] [Related]
19. Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes.
Thrailkill KM; Moreau CS; Swearingen C; Rettiganti M; Edwards K; Morales AE; Kemp SF; Frindik JP; Fowlkes JL
Diabetes Technol Ther; 2011 Oct; 13(10):1023-30. PubMed ID: 21718094
[TBL] [Abstract][Full Text] [Related]
20. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
